

Published in final edited form as:

Cancer Metastasis Rev.; 44(1): 7. doi:10.1007/s10555-024-10229-z.

## **Retraction Note: EET signaling in cancer**

Dipak Panigrahy<sup>1</sup>, Emily R. Greene<sup>1</sup>, Ambra Pozzi<sup>2</sup>, Dao Wen Wang<sup>3</sup>, Darryl C. Zeldin<sup>4</sup>

<sup>1</sup>Vascular Biology Program, Boston Children's Hospital, Division of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA

<sup>2</sup>Department of Medicine and Cancer Biology, Division of Nephrology and Hypertension, Vanderbilt University, Nashville, TN, USA

<sup>3</sup>Department of Internal Medicine and Gene Therapy Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, People's Republic of China

<sup>4</sup>Division of Intramural Research, National Institute of Environmental Health Science, National Institute of Health, Research Triangle Park, NC, USA

The Editor in Chief has retracted this article because Figure 1 and 3, as well as large part of the text were duplicate from a previously published article by some of the same authors [1]. This article is therefore redundant.

All authors agree to this retraction.

## Reference

1. Panigrahy D, Kaipainen A, Greene ER, et al. (2010). Cytochrome P450-derived eicosanoids: The neglected pathway in cancer. Cancer and Metastasis Reviews, 29, 723–735. 10.1007/s10555-010-9264-x [PubMed: 20941528]

<sup>&</sup>lt;sup>™</sup>Darryl C. Zeldin, zeldin@niehs.nih.gov.